Guardian Partners’s Legend Biotech LEGN Stock Holding History

Guardian Partners’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,500	Closed	-$208K	–	205
2025 Q4	$208K	Buy	+12,500	New	+$358K	0.02%	201

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FBIL

First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Guardian Partners's LEGN Position: Q1 2026 in Review

Guardian Partners sold out of Legend Biotech (LEGN) in Q1 2026, closing a stake of 12,500 shares — an estimated $208K sold.

Guardian Partners first reported a position in LEGN in Q4 2025 and held it in 1 quarter. The position peaked at $208K in Q4 2025. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

Guardian Partners reported no remaining Legend Biotech position as of Q1 2026 after selling out during the quarter.
Guardian Partners sold 12,500 Legend Biotech shares in Q1 2026, an estimated $208K.
Guardian Partners first reported a position in Legend Biotech in Q4 2025 and held it in 1 quarter.
Guardian Partners's Legend Biotech position peaked at $208K in Q4 2025.
189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Guardian Partners's 13F filing for Q1 2026, filed 18 May 2026.